A combination index and glycoproteomics-based approach revealed synergistic anticancer effects of curcuminoids of turmeric against prostate cancer PC3 cells

Wei, Mengmeng; Zhao, Shujuan; Dong, Xue-Man; Wang, Yongjie; Fang, Can; Wu, Pu; Song, Gao-Qian; Gao, Jun-Na; Huang, Zhihui; Xie, Tian; Zhou, Jian

doi:10.1016/j.jep.2020.113467

Cited by 27 publications

(16 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with curcumin monomer, because Curcuma longa extract contains more components, it may play a multitarget and multisignal pathway transduction role in the treatment of OA pain and inflammation in the molecular pathology mechanism [ 56 , 57 ]. Meanwhile, Curcuma longa is a multicomponent botanical drug, and the synergy between its components may bring potential clinical effects in the treatment of OA [ 58 , 59 ]. These components may increase the concentration of each other in the blood of patients with OA through pharmacokinetics and increase the time of each other’s stay in the body, thereby exerting a better clinical effect.…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of Curcuma longa extract and curcumin supplements on osteoarthritis: a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Objective: To assess the efficacy and safety of Curcuma longa Extract and curcumin supplements on osteoarthritis (OA). Methods: The databases such as Pubmed and Cochrane Library were searched to collect the article about Curcuma longa Extract and curcumin in the treatment of OA. Then, randomized controlled trials (RCTs) were selected and their data was extracted. Finally, the RevMan5.3 was utilized for risk of bias assessment and meta-analysis, the STATA15.0 were utilized for publication bias assessment, and GRADE tool were used for the evidence quality assessment of primary outcomes. Results: A total of 15 RCTs involving 1621 participants were included. (1) Compared with placebo, Curcuma longa Extract and curcumin (C.) can decrease the VAS and WOMAC score-pain, the WOMAC score-function and the WOMAC score-stiffness. In terms of adverse events, Curcuma longa Extract and curcumin are comparable to those of placebo. (2) Compared with NSAIDs, Curcuma longa Extract and curcumin have similar effects on joint pain, function and stiffness. The incidence of adverse events in Curcuma longa Extract and curcumin was lower. (3) Compared with the NSAIDs group, C.+NSAIDs can also decrease the VAS and WOMAC score-pain, the WOMAC score-function and the WOMAC score-stiffness. In terms of adverse events, the addition of Curcuma longa Extract and curcumin to NSAIDs did not increase adverse events. Conclusion: Curcuma longa Extract and curcumin may be a safer and effective supplement for OA patients. It is recommended to use Curcuma longa Extract and curcumin supplement for OA patients for more than 12 weeks.

show abstract

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of Curcuma longa extract and curcumin supplements on osteoarthritis: a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Numerous TCMs have been widely used in cancer prevention and treatment in China 34 . SchA is the main active component of Schisandra chinensis (Turcz.)…”

Section: Discussionmentioning

confidence: 99%

“…Breast cancer has huge negative impacts on the life of women across the world because of its high incidence and mortality rates attributed to a lack of effective drugs and preventive measures. Numerous TCMs have been widely used in cancer prevention and treatment in China [ 34 ]. SchA is the main active component of Schisandra chinensis (Turcz.)…”

Section: Discussionmentioning

confidence: 99%

Bio-informatics and in Vitro Experiments Reveal the Mechanism of Schisandrin A Against MDA-MB-231 cells

et al. 2021

View full text Add to dashboard Cite

Schisandrin A (SchA) has been reported to have good anti-cancer effects. However, its anticancer mechanism in breast cancer remains unknown. This study aimed to explore the mechanism of SchA in breast cancer treatment using bio-informatics analysis and in vitro experiments. The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Cards, and PharmMapper databases were used to screen the candidate targets of SchA against MDA-MB-231 cells selected as the tested cell line through MTT analysis. The functions and pathways of the targets were identified using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis and further analyzed using DAVID 6.8.1 database. Network pharmacology analysis revealed 77 candidate targets, 31 signal pathways, and 208 GO entries (P < 0.05). The targets regulated serine-type endopeptidase and protein tyrosine kinase activities, thereby promoting the migration and inhibiting the apoptosis of MDA-MB-231 cells. Comprehensive analysis of the "Protein-Protein Interaction" (PPI) and "Component-Targets-Pathways" (C-T-P) networks constructed using Cytoscape 3.7.1 software revealed four core targets: EGFR, PIK3R1, MMP9 and Caspase 3. Their docking scores with SchA were subsequently investigated through molecular docking. The wound healing, Hoechst 33342/PI, and western blot assays confirmed that SchA significantly down-regulated EGFR, PIK3R1, and MMP9, but up-regulated cleaved-caspase 3, thus inhibiting the migration and promoting the apoptosis of MDA-MB-231 cells. Reckoning the findings of the study, SchA is a potential adjuvant treatment for breast cancer.

show abstract

“…As previously mentioned, it is difficult to make an accurate comparison of the immunomodulatory effects due to miscellaneous reasons, including the complexity of the immune system, a variety of possible immunological outcomes, and lack of clinical trials assessing the differences between therapies. Moreover, it is worth mentioning that most studies do not distinguish an additive effect of a therapy from a synergistic effect, which concerns studies on cytokines expression, in particular, but there are articles that correctly incorporate both terms [ 272 , 273 , 274 , 275 , 276 ]. In the case of studying the immunomodulatory effects of focal therapies, an additive effect may be defined if the level or value of a certain immune property is either equal or lower in the combinational approach than the sum of the values of the effect in the monotherapeutic approach (1 + 1 ≤ 2).…”

Section: Overview Of the Immunomodulatory Effects Of Focal Therapies ...mentioning

confidence: 99%

Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment

Karwacki

Szlasa

Sauer

et al. 2022

Cells

View full text Add to dashboard Cite

Due to its slow progression and susceptibility to radical forms of treatment, low-grade PC is associated with high overall survival (OS). With the clinical progression of PC, the therapy is becoming more complex. The immunosuppressive tumor microenvironment (TME) makes PC a difficult target for most immunotherapeutics. Its general immune resistance is established by e.g., immune evasion through Treg cells, synthesis of immunosuppressive mediators, and the defective expression of surface neoantigens. The success of sipuleucel-T in clinical trials initiated several other clinical studies that specifically target the immune escape of tumors and eliminate the immunosuppressive properties of the TME. In the settings of PC treatment, this can be commonly achieved with radiation therapy (RT). In addition, focal therapies usually applied for localized PC, such as high-intensity focused ultrasound (HIFU) therapy, cryotherapy, photodynamic therapy (PDT), and irreversible electroporation (IRE) were shown to boost the anti-cancer response. Nevertheless, the present guidelines restrict their application to the context of a clinical trial or a prospective cohort study. This review explains how RT and focal therapies enhance the immune response. We also provide data supporting the combination of RT and focal treatments with immune therapies.

show abstract

A combination index and glycoproteomics-based approach revealed synergistic anticancer effects of curcuminoids of turmeric against prostate cancer PC3 cells

Cited by 27 publications

References 42 publications

The efficacy and safety of Curcuma longa extract and curcumin supplements on osteoarthritis: a systematic review and meta-analysis

The efficacy and safety of Curcuma longa extract and curcumin supplements on osteoarthritis: a systematic review and meta-analysis

Bio-informatics and in Vitro Experiments Reveal the Mechanism of Schisandrin A Against MDA-MB-231 cells

Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment

Contact Info

Product

Resources

About